Experimental Drug Shows Promise in Treating Alzheimer's Disease
An experimental drug shows promise in treating Alzheimer’s disease by preventing inflammation and removing abnormal protein clumps in the brain that are associated with the disease. A key characteristic of Alzheimer’s disease is the development of abnormal protein clumps called amyloid plaques and tangled bundles of fibers in the brain. These changes cause inflammation in the brain and damage to the neurons. This progressive damage leads to memory loss, confusion and dementia. The new drug, known as NTRX-07, appears to decrease this inflammation in the brain, while preserving neurons and regenerative cells in the brain. “This drug may reduce inflammation in the brain, which is linked to Alzheimer’s disease,” said lead researcher Mohamed Naguib, MD, a physician anesthesiologist in the Department of General Anesthesiology at the Cleveland Clinic and professor of anesthesiology at the Cleveland Clinic Lerner College of Medicine. “NRTX-07 uses a different mechanism than many other Alzheimer’s drugs currently available, as it targets the cause of the disease, not just the symptoms.” Click here to read more.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada